{
  "docId": "019de074-7886-752e-a283-7bf57c077b30",
  "docSlug": "0ac137ebdbf597da5ec73bb0ea218c10",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 31,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a feature-comparison matrix to highlight the unique value proposition of DMX-1002 (Ibogaine) against standard MAT and withdrawal support drugs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7886-752e-a283-7bf57c077b30/30",
  "deckHref": "/decks/019de074-7886-752e-a283-7bf57c077b30",
  "deckJsonHref": "/decks/019de074-7886-752e-a283-7bf57c077b30.json",
  "deckAnchorHref": "/decks/019de074-7886-752e-a283-7bf57c077b30#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.052,
        "y": 0.218
      },
      "kind": "paragraph",
      "text": "DMX-1002 could potentially become a paradigm-shifting therapy for Opioid Use Disorder (OUD). Current standard of care for OUD is medication therapy, requiring opioid substitutes that carry significant side effects. Current strategies for withdrawal support have high rates of relapse.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea1d7295-3921-4763-89f4-1667e64d09c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.265,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: OUD = Opioid Use Disorder. Source: Publicly available information, including company websites and clinicaltrials.gov, GlobalData, Evaluate Pharma (both as of 2022). 1. Current Standard of Care. 2. Rarely used given high rates of relapse. Used primarily in institutional or penitentiary settings",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ffcb7be-af81-4683-8811-1ec64cf94b8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.7,
        "x": 0.265,
        "y": 0.218
      },
      "kind": "table",
      "text": "Comparison matrix of DMX-1002 vs Methadone, Buprenorphine, Naltrexone, Clonidine, and Lofexidine across 5 therapeutic criteria.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f748282f-359e-4a38-898a-925c9072e52c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.7,
        "x": 0.265,
        "y": 0.078
      },
      "kind": "title",
      "text": "DMX-1002 has the potential to become the first & best in-class treatment for OUD, minimizing risk of relapse",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57885e65-92d9-43bc-b908-9191275470f3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "c445f374-fb51-43ce-80b5-bec28dd26b63",
      "evidence": "The slide uses a feature-comparison table to position the product against competitors.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}